На главную
Результаты поиска “U.S. Pharmaceutical Sales Statistics” за 2015
B2B Sales Job Interview Preparation - Five Tips to Get Hired!
 
06:09
My YouTube Video Gear Kit - http://geni.us/17Iz8 Edit videos with FCPX - http://geni.us/LNR1F9 Camera microphone - http://geni.us/fTsnqFL Website - http://geni.us/n1Bu Facebook - http://geni.us/92Qk Instagram - http://geni.us/vOEm8 YouTube - http://geni.us/qWYWHhR Twitter - http://geni.us/ZK8BN LinkedIN - http://geni.us/SejN1W1 Kit - http://geni.us/17Iz8 Sales Job Interview Preparation - Things to Know! When interviewing for a sales position, here are some fundamental questions you should be ready to answer if you want to get the job. For more sales tips go to http://www.VictorAntonio.com #salesmotivation #salestips #jobinterview
Просмотров: 171778 Victor Antonio
The Truth About Cancer: A Global Quest - Episode 1
 
01:58:50
!! Free "A Global Quest" Episode 1!! "The True History of Chemotherapy & The Pharmaceutical Monopoly" If you would like to support our mission and own all Episodes of this eye-opening Docu-Series, please follow this link: http://bit.ly/agq-silver-ttac-yt --------------------------------------------------- Welcome to Episode 1 of "The Truth About Cancer: A Global Quest". This Episode is about the true history of Chemotherapy and the pharmaceutical monopoly. We welcome you to watch this Episode completely free. To watch Episode 2 of "A Global Quest" docu-series for FREE, click here: https://youtu.be/VK_sX5ko8SE Join TTAC's 900K+ FB fans: http://bit.ly/TTAC-Facebook-YT Follow us on PINTEREST: http://bit.ly/TTAC-Pinterest-YT Find us on INSTAGRAM: http://bit.ly/TTAC-Instagram-YT Visit our website: www.thetruthaboutcancer.com Our mission is to educate the world, expose lies & empower people with life-saving knowledge. Help us and share the truth, by clicking the SHARE button above! -------------------------------------------------- About The Truth About Cancer -------------------------------------------------- The Truth About Cancer’s mission is to inform, educate, and eradicate the pandemic of cancer in our modern world. Every single day, tens of thousands of people just like you are curing cancer (and/or preventing it) from destroying their bodies. It’s time to take matters into your own hands and educate yourself on real cancer prevention and treatments. It could save your life or the life of someone you love. ---------------------------------------------------------------------- Inside The Truth About Cancer Docu-Series --------------------------------------------------------------------- Doctors, researchers, experts, and survivors show you exactly how to prevent and treat cancer in our 3 original docu-series: "The Quest For The Cures”, “The Quest For The Cures Continues”, “The Truth About Cancer: A Global Quest”, and on our website: http://www.thetruthaboutcancer.com In our docu-series you’ll travel with Ty Bollinger who lost both his mother and father to cancer (as well as 5 other family members). Ty travels the country and the globe and sits down with the foremost doctors, researchers, experts, and cancer conquerers to find out their proven methods for preventing and treating cancer. Please join our email list to be notified of all upcoming events (including free airings of our docu-series): http://bit.ly/join-ttac-mission-yt Learn more about our latest docu-series “The Truth About Cancer: A Global Quest” here: http://bit.ly/agq-silver-ttac-yt --------------------------------------- About Ty Bollinger --------------------------------------- Ty Bollinger is a devoted husband, father, a best-selling author, and a Christian. He is also a licensed CPA, health freedom advocate, cancer researcher, former competitive bodybuilder, and author of the best-selling book "Cancer - Step Outside the Box," which has sold over 100,000 copies worldwide. After losing his mother and father and several family members to cancer, Ty’s heartbreak and grief coupled with his firm belief that chemotherapy, radiation, and surgery were the NOT the most effective treatments available for cancer patients led him on a path of discovery. He began a quest to learn everything he possibly could about alternative cancer treatments and the medical industry. What he uncovered was shocking. On his journey, he’s interviewed cutting-edge scientists, leading alternative doctors, and groundbreaking researchers to learn about hidden alternative cancer treatments. What he uncovered help to create The Truth About Cancer and its 3 awe-inspiring docu-series’:”The Quest for The Cures”, “The Quest For The Cures Continues”, and “The Truth About Cancer: A Global Quest.” Ty has touched the hearts and changed the lives of thousands of people around the world. Ty speaks frequently at conferences, local health group meetings, churches, and is a regular guest on multiple radio and TV shows and writes for numerous magazines and websites. ---------------------------------------------------------------------------------------------------------------- thetruthaboutcancer, chemo truths, the truth about cancer, ty bollinger, truth about cancer, a global quest, truth about cancer global quest episode 1, truth about cancer episode 1, a global quest episode 1, does chemotherapy work, alternative cancer cures, how to beat cancer with natural cures, cancer truths, chemotherapy side effects, which natural cancer treatments work, best natural cancer treatment, what is the best treatment for breast cancer, best food to cure cancer
Просмотров: 3393721 The Truth About Cancer
Probability-based forecasting for U.S. generic drug sales.
 
03:28
Value of Insight VoiConsulting.com.
Просмотров: 347 Value Of Insight
Why have a registration exam?
 
03:42
GPhC head of education, Damian Day, explains why having an exam as a requirement to join the register as a pharmacist is effective.
Просмотров: 1567 General Pharmaceutical Council
Let’s Be Honest: If Any Republican Wins In 2016, We’re Screwed - The Ring Of Fire
 
03:18
For the last week, I’ve been thinking about what I saw in the Republican debates. I’ve read analyses from every possible source, and I think what bothers me the most is that no one is saying the painfully obvious: If any one of those people that we saw on the stage last Wednesday night wins the presidency, then we, as a country, are completely screwed. I’m incredibly concerned about the fact that not one single Republican that took the stage that night was able to offer a single, cohesive, coherent policy plan. ON ANY ISSUE. The only thing that came close were their insane ideas to build a wall along the Southern border and to bomb the Middle East into oblivion. But those are the same backwards ideas that the Republican Party has been offering up for 35 years. Follow more of our stories at http://www.RingofFireRadio.com Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Listen to Ring of Fire on Saturdays from 3pm - 6pm Eastern! Listen live via the Progressive Voices Channel on TuneIn: http://tunein.com/radio/Progressive-Voices-s189055/ Or find a station here: http://www.ringoffireradio.com/station/ Watch Ring of Fire every weekday at 8:30pm EST on Free Speech TV! Support Ring of Fire by subscribing to our YouTube channel: http://www.youtube.com/user/golefttv You can also support us here: http://www.ringoffireradio.com/support/ Your continued support keeps Ring of Fire on the air! Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Support us further by shopping on Amazon via our Amazon-Ring of Fire partnership link. A portion of the sales will come back to Ring of Fire at no extra cost to you. Bookmark and follow the link below and continue shopping as usual! Amazon - Ring of Fire partnership link: http://www.amazon.com/?tag=rinoffir-20
Просмотров: 5241 The Ring of Fire
Biopharmaceutical Company Beats on Earnings on Growing Sales of Depression Drug
 
00:50
Drug maker Bristol Myers (BMY) posted earnings of $0.71 per share on Tuesday, beating analyst estimates. Revenue was also higher than expected, coming in at $4.04B - a 6 percent increase on last year's numbers.The bio-pharmaceutical company benefited from increased sales of its depression treatment Abilify this quarter, but is facing competition from similar copies of the drug in the US. The New York based company was hit by the strong dollar but remains optimistic about its pipeline of immunotherapy cancer drugs and latest Hepatitis C treatments. Sales of the company's latest cancer drug Opdivo missed Wall Street expectations which knocked the stock price in this morning. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 83 TheStreet: Investing Strategies
Bernie Sanders' Thoughts on Drug Company Fraud and High Cost of Medicine in America
 
07:13
On May 23, 2012, Senator Bernie Sanders criticized the exorbitant prices Americans pay for prescription drugs and the enormous amount of fraud that takes place within the pharmaceutical industry. Link: http://www.sanders.senate.gov/newsroom/press-releases/sanders-crack-down-on-pharmaceutical-fraud Abbott Labs, which agreed last month to pay $1.6 billion for illegally marketing the anti-seizure drug Depakote. The New York Times said the company also agreed to plead guilty to one misdemeanor charge for violating the Food, Drug and Cosmetic Act for misbranding. Abbott Labs agreed to pay $421 million in 2010, along with two smaller companies, to settle charges that they deliberately spiked drug costs by up to 10 times the actual cost in order to boost reimbursements from Medicare and Medicaid. Pfizer, which paid $49 million to settle charges that a subsidiary defrauded the Medicaid program by overcharging for the cholesterol-lowering drug Lipitor. A division of Pfizer pleaded guilty to two felonies and agreed to pay $430 million to settle charges that it fraudulently promoted the drug Neurontin for a string of unapproved uses. GlaxoSmithKline, which in 2011 reached an "agreement in principle" to pay $3 billion to conclude the company's most significant ongoing federal government investigations into illegal sales and marketing practices for a diabetes drug that was severely restricted last year after it was linked to heart risks. Merck, which in 2009 reached a $670 million settlement for fraud on patients and Medicare/Medicaid involving a conspiracy with hospitals to give the elderly cheaper drugs but charging them for the more expensive product prescribed by the patients' doctors. Merck last year pleaded guilty to a criminal misdemeanor charge and paid a $950 million settlement for illegally promoting Vioxx for rheumatoid arthritis before that use was approved. Vioxx was linked to thousands of heart attacks and sudden cardiac deaths before it was pulled from the market in 2004. Johnson & Johnson last year illegally marketed Risperdal, an anti-psychotic medication, to nursing home patients, and paid over $2 billion in fines, a mere 6.3 percent of sales from the drug. www.ouramazingworld.org FB.com/ouramazingworldd Twitter.com/OAWoww
Просмотров: 1641 Our Amazing World
Global Cervical Cancer Drug Industry 2015 Market Research Report
 
00:31
Big Market Research “Global Cervical Cancer Drug Industry” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast. The Global Cervical Cancer Drug Industry 2015 Deep Market Research Report is a professional and in-depth study on the current state of the Cervical Cancer Drug industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Cervical Cancer Drug market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. Read more details at: http://www.bigmarketresearch.com/global-cervical-cancer-drug-industry-2015-deep-research-report-market The Global Cervical Cancer Drug Industry, report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Cervical Cancer Drug industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. With 164 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Table of Contents 1 Industry Overview 1.1 Definition and Specifications of Cervical Cancer Drug 1.2 Classification of Cervical Cancer Drug 1.3 Applications of Cervical Cancer Drug 1.4 Industry Chain Structure of Cervical Cancer Drug 1.5 Industry Regional Overview of Cervical Cancer Drug 2 Manufacturing Cost Structure Analysis of Cervical Cancer Drug 2.1 Raw Material Suppliers and Price Analysis of Cervical Cancer Drug 2.2 Equipment Suppliers and Price Analysis of Cervical Cancer Drug 2.3 Labor Cost Analysis of Cervical Cancer Drug 2.4 Other Costs Analysis of Cervical Cancer Drug 3 Technical Data and Manufacturing Plants Analysis 3.1 Capacity and Commercial Production Date of Global Key Manufacturers in 2014 3.2 Manufacturing Plants Distribution of Global Key Cervical Cancer Drug Manufacturers in 2014 3.3 R&D Status and Technology Source of Global Cervical Cancer Drug Key Manufacturers in 2014 3.4 Raw Materials Sources Analysis of Global Cervical Cancer Drug Key Manufacturers in 2014 4 Production Analysis of Cervical Cancer Drug by Regions, Technology, and Applications 4.1 Global Production of Cervical Cancer Drug by Regions (US, EU, China, Japan, etc.) 2010-2015 4.2 Global Production of Cervical Cancer Drug by Technology 2010-2015 4.3 Global Production of Cervical Cancer Drug by Applications 2010-2015 4.4 Price Analysis of Global Cervical Cancer Drug Key Manufacturers in 2015 5 Sales and Revenue Analysis of Cervical Cancer Drug by Regions 5.1 Global Sales of Cervical Cancer Drug by Regions (US, EU, China, Japan, etc.) 2010-2015 5.2 Global Revenue of Cervical Cancer Drug by Regions (US, EU, China, Japan, etc.) 2010-2015 5.3 Global Price Analysis of Cervical Cancer Drug Sales by Regions (US, EU, China, Japan, etc.) 2010-2015 5.4 Global Price, Cost and Gross of Cervical Cancer Drug 2010-2015 6 Analysis of Cervical Cancer Drug Production, Supply, Sales and Market Status 2010-2015 6.1 Capacity and Production of Cervical Cancer Drug 2010-2015 6.2 Production Market Share Analysis of Cervical Cancer Drug 2010-2015 6.3 Sales Overview of Cervical Cancer Drug 2010-2015 6.4 Supply, Sales and Shortage of Cervical Cancer Drug 2010-2015 Enquire about report: http://www.bigmarketresearch.com/report-enquiry/300004
Просмотров: 43 Moira Warren
2 Critical Tips To Becoming An Entrepreneur
 
03:28
http://www.talljeff.com/becoming-an-entrepreneur/ Considering becoming an entrepreneur? Always had the ‘bug’ to start your own thing? Here’s 2 tips I found that were critical to becoming an entrepreneur. Both of my parents and my entire family were employees. My Father was in a corporate sales job and my Mother was a school teacher. They provided a comfortable upbringing for us, good values and were hard working folks. So the roadmap for becoming an entrepreneur was not clearly defined for me. Perhaps not for you, too. In 1900 over 90% of Americans were self-employed; only 10% worked for someone else. Fast-forward just 80 years to 1980 and the numbers are reversed, roughly 90% work for someone else and 10% are self-employed. Quite a shift! Full disclosure, at the time of this writing I work for someone else. I work in Corporate America and I’m a Reserve Officer in the Army. Be proud of your employer, give them a hard days work. They deserve it! But do you deserve more? Are you 100% satisfied in your life at the present? Your income? Your freedom? Your lifestyle? Your real quality of life? Heck even having a day off here and there – when you want to! I wasn’t. I wanted more. A few short years ago I began to think bigger. Heck I was downsized right out of my pharmaceutical sales job, so I had to look at other options… And fast! That day when I was handed a pink slip right over the phone began my journey to becoming an entrepreneur… Becoming An Entrepreneur: What Is It Exactly? So here is the textbook definition of an entrepreneur, straight from Wikipedia… Entrepreneurship is the process of starting a business or other organization. The entrepreneur develops a business plan, acquires the human and other required resources, and is fully responsible for its success or failure. What do I see when I read this? Hard work! You betcha! A lot of it :-) Yes you are responsible for the success or failure of your enterprise. The buck stops with you! What I also see is complete autonomy, unlimited income, flexibility and ultimately freedom. Now it will take time, nothing is get rich quick. However becoming an entrepreneur for me has been one of the most rewarding (and frustrating) ventures I have entered in my life. Entrepreneurship isn’t perfect, it’s a just a better way! My goal here at TallJeff.com is to shorten the learning curve for you. Save you some headaches on the mistakes I made. To give you some tips and training to help you along on your journey to becoming an entrepreneur. Full blog article right here http://www.talljeff.com/becoming-an-entrepreneur/ Leave a comment or question if ya got value and thank you! :-) Jeff McGeary jeff@talljeff.com http://www.talljeff.com Connect with me: http://www.facebook.com/jeffmcgearypage http://www.twitter.com/jeffmcgearypage http://www.pinterest.com/jeffmcgearypage http://www.linkedin.com/in/jeffmcgeary Don't forget to hit the red "SUBSCRIBE" button (right below my video) for more free training!
Просмотров: 32 Jeff McGeary
Pfizer Beats On Earnings As Cancer Drugs Boost Q2 Performance
 
00:56
Pfizer (PFE) reported earnings on Tuesday that beat estimates and raised its outlook for the year as newly launched drug treatments continued to perform well in the the second quarter. The company's new breast cancer drug Ibrance generated $140 million in sales following its approval back in February. The drug has been shown to slow the growth of tumors in women with advanced stage breast cancer. The pneumonia vaccine Prevnar 13 also saw strong sales as the global vaccine unit saw revenue jump 44 percent. Pfizer's other oncology drug sales also saw a a 25 percent increase on last year's numbers. Pfizer has adjusted its profit guidance for 2015 from $1.95 to $2.05, up to $2.01 to $2.07 per share. The company also expects sales to reach between $45 and $46 billion. Overall, the drug maker posted earnings of $0.56 per share, down from last year's $0.58 per share. revenue was down about 7 percent to 11.9 billion but still beat estimates. Shares in Pfizer were up on the earnings news despite the dip in profits and the headwinds from the strong dollar, which slashed around $1 billion off the company's revenue numbers. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 179 TheStreet: Investing Strategies
Statistical Analysis and Interpretation Why it is important for a Master's Student
 
00:46
http://www.statswork.com/ . Statswork has been established with an outlook to provide high quality statistical and biostatistical services to a wide range of industry sectors that includes: Corporate Academic FMCG Logistics R & D Pharmaceutical and Banking Based on our vast experience spanning over 15 years, we have been able to deliver services that are accurate, concise and extremely intrinsic to overall business and academic objectives. Our highly qualified personnel, trained from reputed international universities like Harvard are well experienced in supporting clients with the requisite skills and know-how to execute complex statistical / biostatistical analysis and research activities. Our repertoire for servicing fortune 500 companies has propelled us to the forefront, thereby emerging as a trusted name in the field of statistical and biostatistical analytics.
Просмотров: 446 Stats Work
Pfizer, Allergan Create Largest Pharmaceutical Merger
 
01:44
Pfizer and Allergan are set to reach a $150 billion deal that would create the world's largest drug maker in terms of sales, according to the Wall Street Journal.
Просмотров: 260 CBN - The Christian Broadcasting Network
How Big Oil Conquered the World
 
01:11:27
TRANSCRIPT AND SOURCES: https://www.corbettreport.com/?p=16888 From farm to pharmaceutical, diesel truck to dinner plate, pipeline to plastic product, it is impossible to think of an area of our modern-day lives that is not affected by the oil industry. The story of oil is the story of the modern world. And this is the story of those who helped shape that world, and how the oil-igarchy they created is on the verge of monopolizing life itself.
Просмотров: 985699 corbettreport
Newsworthy Numbers - Part 1
 
01:02
British researchers found that study participants with Vitamin D levels below 50 nanomoles per liter, the minimum healthy level, were up to two times more likely to suffer from dementia than those with higher levels. $7.9 billion is the amount of money spent last year on Sovaldi, a treatment for hepatitis C and the prescription drug with the highest U.S. sales. Last year, spending on prescription drugs reached $374 billion. That’s up 13% from 2013 according to a study by the IMS Institute for Healthcare Informatics. 270 servings per person per year, that’s the volume of single-serve, unflavored bottled water in the U.S. marketplace.
Просмотров: 10 HometownHealth
What Is Distribution Selling?
 
02:15
What Is Distribution Selling?. Part of the series: Marketing and Maintaining Your Small Business. Distribution selling plays a large part in many small businesses. Learn about distribution selling with help from a business consultant and marketing expert in this free video clip. Read more: http://www.ehow.com/video_12215001_distribution-selling.html
Просмотров: 360 ehowfinance
#123: Technology and Strategy in Biotech, with Andi Karaboutis, Executive Vice President, Biogen
 
46:27
Technology plays a foundational role in biotech and the pharmaceutical industry. In this episode, we discuss the intersection of technology and strategy with one of the industry's leading executives, who also happens to be a woman. Andi Karaboutis is Executive Vice President Technology & Business Solutions at Biogen, located in Cambridge, MA. She is accountable for technologies that provide insights for drug discovery and patient benefit. For more information, go to https://www.cxotalk.com/technology-strategy-biotech-andi-karaboutis-executive-vice-president-biogen ------------------ Check out all the CXOTALK episodes: https://cxotalk.com/episodes ------------------ Follow us on Twitter: https://twitter.com/cxotalk ------------------
Просмотров: 873 CXOTALK
Pharmaceutical Company Cuts Outlook Due to Patent Expirations and Strong Dollar
 
00:48
Pfizer's (PFE) new drugs pipeline gave their first quarter earnings a boost on Tuesday. The company beat estimates posting profits of $2.4B or $0.51 per share. Revenue was down on last year's numbers, coming in at $10.86 billion. The pharmaceuticals giant was hurt by the strong dollar and a wave of patent expirations. Pfizer cut its full year outlook for 2015 and lowered revenue forecasts to to $46.5 billion. The company saw a 44% increase in global vaccine revenue and agreed to buy injectable drugs maker Hospira for $16 billion back in February. Pfizer stock is up around 11 percent this year. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 84 TheStreet: Investing Strategies
This Is How I Talk - SNL
 
04:51
After getting caught imitating his boss (Leslie Jones), a new employee (Louis C.K.) must play off the impression as his real talking voice in order to not get fired. Subscribe to the SNL channel for more clips: http://goo.gl/24RRTv Download the SNL App for free: http://www.nbc.com/saturday-night-live/app For more SNL 40th Anniversary Special: http://goo.gl/gLyPTc Get more SNL on Hulu Plus: http://www.hulu.com/saturday-night-live Get more SNL: http://www.nbc.com/saturday-night-live Full Episodes: http://www.nbc.com/saturday-night-live/video Like SNL: https://www.facebook.com/snl Follow SNL: https://twitter.com/nbcsnl SNL Tumblr: http://nbcsnl.tumblr.com/ SNL Instagram: http://instagram.com/nbcsnl SNL Google+: https://plus.google.com/+SaturdayNightLive/ SNL Pinterest: http://www.pinterest.com/nbcsnl/
Просмотров: 10294235 Saturday Night Live
Lupin Q4 Net Profit Slips; Slow Growth Dents Margins: Interview with CEO, Nilesh Gupta
 
13:39
Drug firm Lupin saw consolidated net profit fell 1.1 percent to Rs 547 crore in January-March quarter from Rs 553 crore in the corresponding quarter last fiscal. During the period, its revenue was alm
Просмотров: 380 CNBC-TV18
Nightly Business Report: Hepatitis C drug pricing weighs on Gilead
 
02:09
Gilead said in its earnings report that it gave insurers steeper-than-expected discounts on its hepatitis C drugs.
Просмотров: 225 NBRbizrpt
Global Disposable Medical Gloves Industry 2015 Deep Market Research Report
 
00:31
Big Market Research “Global Disposable Medical Gloves Industry” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast to 2020. The Global Disposable Medical Gloves Industry 2015 Deep Market Research Report is a professional and in-depth study on the current state of the Disposable Medical Gloves industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Disposable Medical Gloves market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. Read more details at: http://www.bigmarketresearch.com/global-disposable-medical-gloves-industry-2015-deep-research-report-market The Global Disposable Medical Gloves Industry, report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Disposable Medical Gloves industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. With 165 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Table of Contents 1 Industry Overview 1.1 Definition and Specifications of Disposable Medical Gloves 1.2 Classification of Disposable Medical Gloves 1.3 Applications of Disposable Medical Gloves 1.4 Industry Chain Structure of Disposable Medical Gloves 2 Manufacturing Cost Structure Analysis of Disposable Medical Gloves 2.1 Raw Material Suppliers and Price Analysis of Disposable Medical Gloves 2.2 Equipment Suppliers and Price Analysis of Disposable Medical Gloves 2.3 Labor Cost Analysis of Disposable Medical Gloves 2.4 Other Costs Analysis of Disposable Medical Gloves 3 Technical Data and Manufacturing Plants Analysis 3.1 Capacity and Commercial Production Date of Global Key Manufacturers in 2014 3.2 Manufacturing Plants Distribution of Global Key Disposable Medical Gloves Manufacturers in 2014 3.3 R&D Status and Technology Source of Global Disposable Medical Gloves Key Manufacturers in 2014 3.4 Raw Materials Sources Analysis of Global Disposable Medical Gloves Key Manufacturers in 2014 4 Production Analysis of Disposable Medical Gloves by Regions, Technology, and Applications 4.1 Global Production of Disposable Medical Gloves by Regions (US, EU, China, Japan, etc.) 2010-2015 4.2 Global Production of Disposable Medical Gloves by Technology 2010-2015 4.3 Global Production of "& B1 &" by Applications 2010-2015 4.4 Price Analysis of Global Disposable Medical Gloves Key Manufacturers in 2015 5 Sales and Revenue Analysis of Disposable Medical Gloves by Regions 5.1 Global Sales of Disposable Medical Gloves by Regions (US, EU, China, Japan, etc.) 2010-2015 5.2 Global Revenue of Disposable Medical Gloves by Regions (US, EU, China, Japan, etc.) 2010-2015 5.3 Global Price Analysis of Disposable Medical Gloves Sales by Regions (US, EU, China, Japan, etc.) 2010-2015 5.4 Global Price, Cost and Gross of Disposable Medical Gloves 2010-2015 6 Analysis of Disposable Medical Gloves Production, Supply, Sales and Market Status 2010-2015 6.1 Capacity and Production of Disposable Medical Gloves 2010-2015 6.2 Production Market Share Analysis of Disposable Medical Gloves 2010-2015 6.3 Sales Overview of Disposable Medical Gloves 2010-2015 6.4 Supply, Sales and Shortage of Disposable Medical Gloves 2010-2015 Enquire About Report: http://www.bigmarketresearch.com/report-enquiry/300690
Просмотров: 149 Melvin Wells
As first female libido drug hits the market, more options in
 
00:33
YOUR DESCRIPTION HAS REACHED THE LIMIT OF CHARACTERS ALLOWED AND WAS CUT. WASHINGTON (CBS NEWS) -- Most women with low sexual desire won't rush to get the first prescription drug to boost female libido when it becomes available on Saturday. But they may have more options down the road. Addyi is a daily medication that can't be taken with alcohol or certain other drugs, which will likely limit its use. But experts believe those restrictions could spur development of better treatments for women's sexual problems after more than a decade of neglect by most of the world's large drugmakers. Kim Wallen, a psychology professor at Emory University, says Addyi represents a historic milestone that may open the door to more drugs targeting desire in men and women. Where Viagra and other men's erectile dysfunction drugs work by increasing blood flow to the genitals, Addyi acts on brain chemicals associated with desire. "This is the first time that a drug, for either men or women, has been approved strictly to increase sexual desire," Wallen says. "That legitimizes many other drugs that are in development." Treatments for women's libido issues are an untapped financial opportunity for drugmakers. Analysts estimate the market could be worth over billion, based on academic estimates that between 5 million and 9 million U.S. women may suffer from desire disorders. But the area hasn't been a research priority for drugmakers in many years. Beginning in the 1990s, Pfizer, Bayer and Procter Gamble all studied - then discarded - drugs targeting female libido. Addyi itself was developed by the German conglomerate, Boehringer Ingelheim, then sold to Sprout Pharmaceuticals after the Food and Drug Administration rejected the medication due to lackluster effectiveness and issues like nausea, fatigue and dizziness. It took Sprout four years to win FDA approval for Addyi, which was finally granted in August, on the third try. "They really struggled with this, even agonized over the decision," said CBS News chief medical correspondent Dr. Jon LaPook. "Because they said the benefits were kind of modest and there were some significant side effects they were worried about: dizziness, sleepiness, and when used with alcohol, fainting." The drug, which acts on brain chemicals associated with mood and appetite, will come with a bold warning label about the risks of fainting if combined with alcohol or certain medications. Additionally, doctors and pharmacists must complete an online certification process to show they understand the drug's risks. Dr. Lisa Dabney says several patients have asked her about Addyi, but they generally lose interest after she explains they cannot drink alcohol while taking the daily medication. "It's definitely an option that's going to help patients," says Dabney, of New York's Mt. Sinai hospital. "But it's going to have a limited patient audience because of the alcohol restrictions and the fact that you have to take it every day." Still, some women credit the drug with saving their relationships. Amanda Parrish, 52, had been married for three years when she realized she was avoiding sex with her husband. Her doctor said it was natural to lose sexual interest with age and suggested she try a vibrator. But nothing worked until Parrish enrolled in a trial of Addyi, which was studied in women who report distress due to a lack of libido. "It just brought me back to where I was as far as being flirty and playful," says Parrish, who lives in Nashville. "I went back to the days of leaving notes on his window, in his car, on his mirror in the morning." Sheri Mike, a 34-year-old mother of two, told CBS News she hopes it will make a difference for her. "I've tried vitamins, me and my husband have tried counseling, I've tried hypnotherapy, but none of those have worked," she said."The lack of desire, the lack of sexual thoughts, no libido -- it's just this one area that's kind of holding us back from being truly happy." Experts generally describe Addyi's effect as "modest." In company studies, women taking the drug that's also called flibanserin reported a slight uptick in sexually satisfying events each month. Their answers to separate questionnaires indicated they experienced a slight increase in desire and a slight decrease in stress. Analysts from Evercore ISI estimate Addyi could generate sales of 00 million annually. That's far below the blockbuster numbers once discussed by experts and the billion that Valeant Pharmaceuticals recently agreed to purchase Sprout. But the buyout has revived interest in a handful of competitors developing alternate treatments. Those products include nasal sprays, injections and antidepressant pills. It could be years before any of them reach patients. That's because the field of women's sexual medicine remains a small one, comprised of tiny companies with limited resources. Leading the field is Cranbury, N.J.-based Palatin Technologies Inc. which is studying an injectable
Просмотров: 430 LOCAL 12
Roslyn Schneider, Pfizer discusses early patient engagement in clinical trials
 
03:24
eyeforpharma’s youtube channel now broadcasts the best presentations, chats and interviews from our conferences. eyeforpharma’s mission is to make the pharmaceutical industry more open and valued. Our conferences are where leading minds gather to discuss and share strategies that drive value for patients and shine a light on pharma excellence. Look for talks on patient-centricity, multi-channel marketing, value-added services, real-world data and sales force effectiveness. Get the latest industry insights in your inbox: http://www.social.eyeforpharma.com/newsletter-subscribe Follow eyeforpharma on Twitter: https://www.twitter.com/eyeforpharma Like eyeforpharma on Facebook: https://www.facebook.com/eyeforpharma Subscribe to our channel: https://www.youtube.com/user/eyeforpharma
Просмотров: 201 eyeforpharma
Inside the $160B Pfizer-Allergan Record Deal
 
02:56
Nov. 23 -- Pfizer Inc. and Allergan Plc said they would combine operations in a stock transaction worth about $160 billion, creating a drugmaking behemoth with products from Viagra to Botox and a low-cost tax base. Jefferies Chief Market Strategist David Zervos and Bloomberg's Cynthia Koons speak on "Bloomberg ‹GO›."
Просмотров: 4701 Bloomberg
Healthcare: Top 3 Drug Approvals of 2015 *** INDUSTRY FOCUS ***
 
21:18
This episode we're highlighting what we think are the most significant, needle-moving drugs to hit the market this year. This podcast was recorded on 12/2/2015. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool
Просмотров: 144 The Motley Fool
Hold IPCA Laboratories, says Mayuresh Joshi
 
02:47
Mayuresh Joshi says that If one looks at the import ban and the statistics involved with the US sales for Ipca Laboratories, FY14 as a perspective, they contributed around Rs 414 odd crore which is 12 percent of the total sales, 20 percent of their exports and if I distinguish between domestic and EPI – its around 61:39 ration. Having said that, couple of their molecules from the Ratlam facility has not been affected by the ban and they probably account around 45 percent of the US sales. Investors should hold on to the stock. We are very optimistic on the stock from FY17 perspective.
Просмотров: 431 Angel Broking
Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals
 
01:13
1. Investigation of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals Bowel Disorders Market is Buoyant and Poised for Growth NBB6-52 November 2012 2. ContentsSection Slide Numbers Executive Summary 14 Market Overview 20 • Definitions 21 • Overview of Inflammatory Bowel Disease 23 o Incidence and Prevalence of Inflammatory Bowel Disease 24 o Diagnosis of Inflammatory Bowel Disease 25 o Clinical Severity of Inflammatory Bowel Disease 27 o Assessment of Disease Activity in IBD Clinical Trials 29 o Anatomic Extent of Ulcerative Colitis 31 o Clinical Guidelines 33 • Overview of Irritable Bowel Syndrome 38 o Diagnosis of IBS 39 o Assessment of Disease Activity in IBS Clinical Trials 40 o Clinical Trial Design Guidance—IBS 41 o Clinical Guidelines—IBS 43 • Personalized Medicine in Bowel Disorders 44 • Key Questions This Study Will Answer 45 • Market Overview—Segmentation 46NBB6-52 3. Substance (continued)Section Slide Numbers External Challenges: Drivers and Restraints 57 Forecasts and Trends 69 Demand Analysis 84 Market Share and Competitive Analysis 87 Inflammatory Bowel Disease Prescription Pharmaceuticals Segment 123 •5-ASA Subsegment Breakdown 127 •Corticosteroid Subsegment Breakdown 138 •TNF Inhibitor Subsegment Breakdown 149 •Non-TNF Biologicals Subsegment Breakdown 160 •Novel Orals Subsegment Breakdown 169 Irritable Bowel Syndrome Prescription Pharmaceuticals Segment 177 The Last Word (Conclusions and Implications) 188 Game-changing Strategies 193 Appendix 195NBB6-52 4. Research TeamLead Analyst Contributing AnalystDeborah Toscano Jennifer BriceSenior Industry Analyst Global Program ManagerLife Sciences Life SciencesResearch Director Strategic Review Committee LeaderDaniel Ruppar Greg CaressiResearch Director Sr. Bad habit PresidentHealthcare HealthcareNBB6-52 5. Official Summary—CEO's Perspective Growth opportunity in the IBD business sector lies in 1 presentation of enhanced items, though the IBS business sector is generally undiscovered. Comfort, adequacy, security, and bearableness 2 are fundamental to the accomplishment of new treatments. More medication treatments must be created for 3 IBD patients who come up short first line treatments. Gastrointestinal inside scatters influence a 4 extensive populace over a wide demographic. Techniques to streamline tolerant adherence to 5 treatment could significantly enhance general clinical results and item achievement. Source: Frost & Sullivan analysis.NBB6-52 6. Market Overview—Segmentation Total Bowel Disorders Prescription Pharmaceuticals Market: Market Segmentation, U.S., 2011 Total Bowel Disorders Prescription Pharmaceuticals Market IBS IBD IBS-C IBS-D CD* UC* Oral or Injectable Treatments Topical Treatments***Considered by and large in forecasts** Not assessed in this exploration Source: Frost & Sullivan examination. NBB6-52 7. Market Overview—Segmentation (proceeded with) Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Market Segmentation, U.S., 2011 Inflammatory Bowel Disease Prescription Pharmaceuticals Market CD UC Oral or Injectable Treatments Topical Treatments* 5-ASA Antibiotics* Corticosteroid Antimetabolite* Biologicals Novel Orals** ASA Corticosteroid TNFs Non-TNF Biologicals•Not secured in this examination service** Investigational; none yet sanction for IBD Source: Frost & Sullivan investigation. NBB6-52 8. Market Overview—Segmentation (proceeded with) Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Market Segmentation, U.S., 2011 Irritable Bowel Syndrome Prescription Pharmaceuticals Market IBS-C IBS-M* IBS-D 5-HT3 (serotonin) Chloride channel (ClC-2) activator (diuretic) adversary Guanylate cyclase sort C receptor agonist*Not secured in this exploration benefit because of absence of sanction therapiesNote: Subsegmentation of the IBS business sector portion is not gave because of low level of business movement Source: Frost & Sullivan examination. NBB6-52 9. Market Overview—Segmentation (proceeded with) Total Bowel Disorders Prescription Pharmaceuticals Market: Percent Sales Breakdown by Drug Class, U.S., 2011 IBS-C Drugs, 5.5% IBS-D Drugs, 1.1% Corticosteroids, 8.6 % TNF inhibitors, 48.7% Biologicals, 49.5% 5-ASA, 35.3% Non-TNF biologicals, 0.8% Note: All figures are adjusted. The base year is 2011. Source: Frost & Sullivan analysis.NBB6-52
Просмотров: 22 DailySlides
Why is College So Expensive?
 
04:54
College is a good deal, but it could be a much better deal. A combination of factors have driven the costs of higher education in America to increase extremely quickly, pricing some people out of an education and building over a trillion dollars in student loan debt. So why? Why did those costs increase and what are schools spending all that fat cash on. Turns out, it's pretty complicated. Can you lower your student loans? http://www.vox.com/2014/10/1/6050243/student-loan-repayment-options SOURCES Trends in College Spending: 1998 to 2008 http://www.deltacostproject.org/sites/default/files/products/Trends-in-College-Spending-98-08.pdf Trends in College Spending 2001 to 2011: http://www.deltacostproject.org/sites/default/files/products/Delta%20Cost_Trends%20College%20Spending%202001-2011_071414_rev.pdf Vox.com - Everything you need to know about Student Debt: http://www.vox.com/cards/student-debt/what-is-a-student-loan Vox.com - Everything you need to know about college costs: http://www.vox.com/cards/college-costs/what-is-college Is Starting College and Not Finishing That Bad? http://www.hamiltonproject.org/papers/what_happens_to_students_who_fail_to_complete_a_college_degree_is_some/ Public Colleges Revenue Shift: https://www.insidehighered.com/news/2015/04/13/report-shows-public-higher-educations-reliance-tuition\ Tuition Fees and Room and Board over time: http://trends.collegeboard.org/college-pricing/figures-tables/tuition-fees-room-board-time Hiring Spree Fattens College Bureaucracy: http://www.wsj.com/articles/SB10001424127887323316804578161490716042814 Problematic Boom in Higher Education Administrators: http://www.huffingtonpost.com/2014/02/06/higher-ed-administrators-growth_n_4738584.html ---- Subscribe to our newsletter! http://nerdfighteria.com/newsletter/ And join the community at http://nerdfighteria.com http://effyeahnerdfighters.com Help transcribe videos - http://nerdfighteria.info John's twitter - http://twitter.com/johngreen John's tumblr - http://fishingboatproceeds.tumblr.com Hank's twitter - http://twitter.com/hankgreen Hank's tumblr - http://edwardspoonhands.tumblr.com
Просмотров: 881042 vlogbrothers
RANBAXY LABORATORIES LTD - Recruitment Notification 2017– Jobs,Openings,Exam dates & results
 
03:41
Latest RANBAXY LABORATORIES LTD Recruitment Notification 2017. Apply today for Jobs & Careers at RANBAXY LABORATORIES LTD – Trainee jobs,The Govt jobs and Employment News channel from Freshersworld.com – The No.1 job portal for freshers in India. Visit http://www.freshersworld.com/ranbaxy-laboratories-jobs-careers/4444191?src=Youtube for detailed job information, recruitment notification, eligibility criteria, application form, general dates, exam results of RANBAXY LABORATORIES LTD. Ranbaxy Laboratories Ltd is a multinational pharmaceutical company that is based in India. The company spends its maximum resources on research and development department. Thus, the number of candidates being selected in R&D is higher than other departments. When it comes to research, the candidates with master degree and doctoral in various fields of medical sciences are usually preferred. Doctors with MD degree are chosen for researcher field. Candidates with doctoral in biotechnology, pharmaceutical or other allied fields are chosen as research assistant. Candidates with master degree in chemistry, biotechnology and other departments are chosen for research associate positions. The Ranbaxy Laboratories limited recruitment happens through campus drive and also through direct recruitment process. The candidates can apply for the positions through the official site. Not just science candidates, the candidates from varying fields like engineering to management are chosen for various departments starting from sales to general administration. When it comes to selection process of Ranbaxy jobs, the candidates have to take up a technical written test, group discussion and personal interview. The written test’s scope, pattern and syllabus would vary based on the educational requirement and type of job profile. The group discussion round would involve a general topic where the communication skills and interpersonal skills of the candidates would be tested. The written test for pharma jobs would not be the same as that of the test for management executives. The group discussion and the other levels would be common for almost all the positions. But, the importance given to each level would vary. When it comes to research and development department, the group discussion would not be of higher value when compared to the sales team recruitment process. .Visit Preparation and placement tips for RANBAXY LABORATORIES LTD jobs at : http://placement.freshersworld.com?src=Youtube For more jobs & career information and daily job alerts, subscribe to our channel and support us. You can also install our Mobile app for govt jobs for getting regular notifications on your mobile. Freshersworld.com is the No.1 job portal for freshers jobs in India. Check Out website for more Jobs & Careers. http://www.freshersworld.com?src=Youtube - - ***Disclaimer: This is just a career guidance video for fresher candidates. The name, logo and properties mentioned in the video are proprietary property of the respective companies. The career and job information mentioned are an indicative generalised information. In no way Freshersworld.com, indulges into direct or indirect recruitment process of the respective companies.
Просмотров: 24862 Freshersworld
Global Cosmetics Market -  Trends, Size, Share, Demand and Forecasts 2020
 
00:51
Big Market Research : Global Cosmetics Market - Size, Share, Trends, Demand, Report, Opportunities and Forecast 2020 To Get More Details @ http://www.bigmarketresearch.com/cosmetics-market Cosmetics are personal care products that are used to enhance and beautify the appearance of individuals. Cosmetics comprise of a mixture of chemical compounds, which are made from synthetics and natural sources. Sun care, skin care, hair care, deodorants, makeup & color cosmetics, and fragrances are some of the popularly used cosmetics. A global increase in the use of sun screen lotions, moisturizing lotions, body lotions, facial wipes, face wash and make up products is fuelling the growth of the global cosmetics market. Retail stores and online portals are the two primary sales channels in this market. Over the past decade, the global cosmetics market has witnessed a steady growth and is anticipated to register a CAGR of 3.7% during the forecast period. Rising consciousness about external appearance among individuals coupled with the rise in disposable income is leading to the increased demand of cosmetics products. Amongst the different key categories of cosmetics, skin & sun care is anticipated to constitute the largest market share of the global cosmetics market throughout the analysis period. The growth is primarily fuelled by the increasing usage of skin & sun care products amongst both men and women. Geographically, Europe dominates the global cosmetics market, accounting for around 1/3rd of the total cosmetics market revenue in 2014. The use of natural and organic beauty products, is a prominent trend which is fostering the growth of the cosmetics market in the region. The rising demand for natural, herbal and organic beauty products creates potential opportunities for manufacturers to innovate and develop newer products to suit consumer preferences. LAMEA (Latin America, Middle East and Africa) region exhibits a dynamic market for cosmetics. The market in the region is estimated to register a CAGR of 4.9% during 2015-2020.
Просмотров: 266 Mack Yosef
Wedding attracts foreign visitors in large numbers
 
03:03
(26 Apr 2011) SHOTLIST 1. Tower of London with tour boat sailing past on river in foreground 2. Tower of London walls and buildings 3. Tourists clambering down stairs on Tower of London rampart 4. Reverse shot of group of American tourists, all dressed identically in red outfits and hats with American flags, looking at Tower of London 5. Front view of Americans standing in line 6. Tourists displaying hands all with identical rings, copies of Kate Middleton's engagement ring 7. SOUNDBITE: (English) Marcia Anderson, 49-year-old pharmaceutical sales representative from Oklahoma City, United States: "London's just a great city. Great history - obviously the Tower and everything here. But then to have the royals and to be able to come and see all the royal things...." SOUNDBITE: (English) Mary Boepple, 49-year-old retiree from Cyprus, Texas, United States - and twin sister of Marcia Anderson: "The thousands of years of history is what's exciting and walking in their (the royal family's) footsteps and enjoy the places that we know that they've been." 8. Tourists walking along Tower of London concourse 9. Tourist taking photograph 10. Tourists walking along walls of Tower of London 11. SOUNDBITE: (English) John Keohane, Chief Yeoman Warder of the Tower of London: "There's so much tradition and this is what I think - especially our visitors from the United States or (elsewhere) abroad - come here to see. They want to come and see all what the British monarchy is all about and why it's so important to all of us that live here in this great country." 12. Group of German tourists looking at guide book 13. Tourists' hands and guide book 14. SOUNDBITE: (German) Jonathan Soenenan, 30 year-old tourist from Berlin, Germany: "We hadn't planned to come here for the royal wedding and it's a coincidence that it's happening while we're here. There's lots going on that we didn't expect, but I might go down on the day and wave at the royal couple!" 15. Tourists walking along concourse 16. SOUNDBITE: (Italian) Massimo Caneva, tourist from Treviso, Italy: "It's fun for the children, especially to see the crown jewels, as well as other things connected to queens and kings, and so they're having a great time." 17. Caneva and family walking away from camera 18. Long shot of Tower of London concourse with tourists walking 19. Tourist taking photograph next to river with Tower of London in background - pans right to show group posing for photograph in front of Tower Bridge 20. Tourists with camera looking at river 21. SOUNDBITE: (English) Jacqueline French, spokesperson for London and Partners, the official promotional agency for London: "What we are hoping is that the royal wedding will really put a spotlight on London. There's an approximate four (b) billion people will be watching the wedding overseas. We've got the queen's jubilee next year, as well as the 2012 Olympic and Paralympic Games. And all of this will create a sense of fun and great atmosphere in London that hopefully people will want to be a part of." 22. Group of tourists by river with map and camera 23. Wide shot of Tower Bridge and River Thames with tourists walking STORYLINE: The British capital is witnessing a boom in tourism ahead of Friday's royal wedding. Some London landmarks are reporting swelling numbers of international visitors, many of whom say they're here primarily because of Prince William and Kate Middleton's 29 April nuptials. Tourists were flocking to the Tower of London on Tuesday. The iconic landmark by the River Thames, with its 900 years of royal history, is a regular stop on the tourist trail. But numbers are definitely up, according to officials. They wore matching red hats, complete with American flags, and identical red outfits. You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/140aeab52eef79898706b0d8f244b330 Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Просмотров: 38 AP Archive
Don't Flush Your Medications! (Extended Message)
 
00:49
The Central Contra Costa Sanitary District reminds you to not flush your pharmaceutical drugs down the toilet. This includes prescription and over the counter medications. Spread the word and help protect the environment! Visit www.centralsan.org for more information.
Просмотров: 113 CentralSanDist
Meet Tania Castillo: Sales Analyst for Univera Healthcare
 
00:30
Photographer. Woodworker. Sales Analyst. See how the many sides of Tania are helping us deliver better coverage to our members.
Просмотров: 13549 Univera Healthcare
How much does it cost to develop a new drug?
 
02:27
Pharmaceutical companies and civil society confront their calculations for the cost of a new drug. Footage: Anne Vigna Edition: Miguel Angel Gavilanes Medicamentalia 2015
Просмотров: 214 Fundación Civio
Johnson & Johnson Pharma Division Provides Earnings Bright Spot
 
00:51
Johnson and Johnson (JNJ) posted earnings on Tuesday that topped Wall Street estimates. The health and personal care giant faced currency headwinds due to the strong dollar but has increased its outlook for 2015, boosting guidance to $6.10-$6.20 per share for the year, up from $6.04-$6.19 per share. The company reported profits of $1.71 per share, up from last year's numbers and beating Wall Street estimates. Revenue was down almost 9 percent from $19.5 billion to $17.8 billion but topped estimates. The brand has topped estimates for the last 17 quarters in a run of over four years. The company's pharmaceutical division was a bright spot. Sales of its arthritis drug Simponi jumped 30 percent in the U.S. market. Johnson and Johnson also announced last month that it had received FDA approval for a new schizophrenia treatment which only needs to be administered four times a year, giving patients greater independence from their dosing. Johnson and Johnson shares have dropped almost 4 percent in the last year. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 125 TheStreet: Investing Strategies
US Anthrax Drugs
 
01:40
Washington, DC Oct. 26, 2001 APTN 1. ws executives coming to microphone 2. cutaway press 3. SOUNDBITE: Chief Operating Officer of GlaxoSmithKline, Bob Ingram, "We have committed that we will work closely with the Food and Drug Administration to expedite the approval for the use of two of our antibiotics, Augmentin and Amoxil against the anthrax strain, and if those are approved we will then donate those free of charge to anyone infected or exposed to anthrax. Secondly, we've sent in our proposal yesterday to commit to supply smallpox vaccine within that one year period we've condensint I hope everyone understands from five to one eight years down to one as several other companies are committing to." 4. ws press 5. SOUNDBITE: Peter Goland, CEO Bristol-Meyers Squibb, "In my company's case, Briston Myers Squibb, we're offering to make our antibiotic available, Tequin, assuming it's approved for the anthrax indication, at no cost to anyone who contracts that illness. Secondly, we're offering 20 to 25 scientists who have experience in antibacterial in voroligy who can work as part of a bioterrorism team to address the country's threats and needs at this time." 6. cutaway press 7. ws executives walking away STORYLINE: Leaders of major pharmaceutical companies detailed steps the companies have taken since September 11 to assist the government's efforts to protect the public health, including providing the public with free anthrax drugs which are alternatives to Cipro. The Pharmaceutical Research and Manufacturers of America (PhRMA) said the companies are coordinating their efforts as part of a newly-created Task Force on Emergency Preparedness. Pharmaceutical companies outlined a wide-range of efforts they are working on to meet new threats at a meeting with Health and Human Services Secretary Tommy Thompson in Washington Friday. Initiatives include offers of free antibiotics to authorities to treat people infected by or exposed to anthrax; offers to develop and manufacture a smallpox vaccine; pledges to increase production of certain medicines as needed; giving government scientists access to company laboratories and production facilities; making company scientists available to work in government facilities as needed. The PhRMA represents the country's leading research-based pharmaceutical and biotechnology companies. The companies are offering an alternative to Cipro, the most popular anthrax drug on the market. The patent-holding maker of Cipro, Bayer Corp., has been ramping up retail production to 100 million tablets by mid-January, according to company officials. That is in addition to the 100 million pills the company agreed to supply to the U.S. government for emergency use at a cost of 95 cents apiece. The government is stockpiling Cipro for use where it is most needed in a national emergency. A jump of nearly 50 percent in prescriptions nationwide for Cipro shows that many doctors and patients are shrugging off government pleas against stockpiling for personal use, medical and industry experts say. In the New York City area, prescriptions nearly tripled, drug marketing data indicate. Spurred by news reports on potential bioterrorism, sales of the antibiotic began climbing right after the Sept. 11 air attacks and weeks before the first news of an anthrax case on Oct. 4, according to a national marketing consultant that surveys pharmaceutical retailers. The numbers are apt to rise more still as they are released in coming weeks, because the latest data go only as far as Oct. 12 - before the last anthrax deaths and widespread Cipro treatment for postal workers. Increases were especially heavy in Washington too, which together with New York suffered the brunt of the Sept. 11 attacks. You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/a50f91724d04280e039ad4aea9dbc2cc Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Просмотров: 92 AP Archive
April 17, 2015 Financial News - Business News - Stock Exchange - NYSE - Market News
 
03:47
April 17, 2015 Financial News - Business News - Stock Exchange - NYSE - Market News CLICK HERE➡ ➡ http://FinancialBuzz.com Business News - Financial News - Stock News -- New York Stock Exchange -- Market News 2015 Business News - Financial News - Stock Exchange -- Wall Street -- Market News - New York Stock Exchange 2015 On Monday, no economic numbers were released, so markets trended downward as everyone waited for the beginning of earnings season. On Tuesday, the producer price index for March rose .2% month to month, up from -.5%, and in line with expectations. Retail sales for March rose .9%, up from -.5%, and slightly below expectations. Markets were mixed, however, energy stocks rallied as crude oil rose nearly 3% to a little over $53 a barrel after forecasters predicted a decline in U.S. shale production. On Wednesday, industrial production for March declined .6%, compared to a .1% increase in February. In addition, the Empire State manufacturing survey for April showed a contraction reading of -1.19, only the second negative reading in the last 23 months. Crude oil continued rising, closing at over $56 a barrel, and this prompted a rally, with the Nasdaq closing above 5,000. On Thursday, housing starts for March were up 2%, disappointing analysts, and jobless claims for the week ending April 11th were up 12,000 to 294,000, higher than expected. On Friday, the consumer price index for March was up .2%, mostly due to higher energy costs. However, news of Greece having debt paying issues, and China's regulators implementing stricter margin regulations, cause a steep drop in markets. Now let’s take a look at some stocks. Mylan (NASDAQ: MYL) shares slumped while shares of Perrigo gained early this week following the news that Mylan, a pharmaceutical company specializing in generic drugs, made a $28.9 billion offer to acquire rival Perrigo. JPMorgan Chase & Co. (NYSE: JPM) shares spiked Tuesday to almost $63, following the release of their first quarter earnings showing a 12% increase in profit. JPMorgan’s net income increased to $5.91 billion on earnings of $1.45 per share, ahead of forecasts of $1.41 per share. The company reported increases in profits across all business units; investment banking up 12%, trading for fixed income, currencies and commodities up 5%, consumer banking up 12% and commercial banking up 1%. Nokia Corporation (NYSE: NOK) and Alcatel-Lucent Alcatel-Lucent (NYSE: ALU) stocks tumbled on Wednesday, after Nokia announced that they will be acquiring the French technology company in an all-stock deal that values Alcatel-Lucent at $16.6 billion. The combined company will have more than 114,000 employees and will be the second largest company in the mobile equipment industry. Citigroup Inc. (NYSE: C) shares made headlines on Thursday, gaining more than 1.5%, after releasing a first quarter earnings report showing the largest earnings the bank has seen in nearly eight years. Operating expenses decreased more than 10% while various business units’ revenue increased. Citigroup’s revenue for the first quarter came in at $19.7 billion or $1.51 per share while analysts forecasted earnings of only $1.39 per share. Netflix, Inc. (NASDAQ: NFLX) stock increased over 18% Thursday, and reached a new 52-week high, after the video streaming company released their first quarter financials, revealing major growth in their subscriber base. They had 4.9 million new subscribers, nearly a million more than what analysts expected. Netflix also reported an increase in revenue of 31%, year-over-year, to $1.4 billion. April 17, 2015 Weekly Stock Market Wrap-up: Mylan (NASDAQ: MYL) JPMorgan Chase & Co. (NYSE: JPM) Nokia Corporation (NYSE: NOK) Alcatel-Lucent (NYSE: ALU) Citigroup Inc. (NYSE: C) Netflix, Inc. (NASDAQ: NFLX) Business News - Financial News - Stock Exchange - New York Stock Exchange -- Wall Street -- Market News 2015 http://www.financialbuzz.com financial news, financial stock news, business news, stock news, financial news today, stock news today 2015, financial news now, stock news now, stock news, business news, financial news, © 2011 Financial Buzz. All rights reserved. No portion of FinancialBuzz.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law
Просмотров: 9378 FinancialBuzzMedia
'Big pharma profiteering must be stopped' – Doctors Without Borders chief
 
02:18
The 2014 Ebola epidemic highlighted the global threat of disease. And while the need for new drugs and vaccines is clear, the research is often driven by profit. How can these opposites be reconciled, and what challenges do aid organisations face in the field? Oksana is joined by Dr Joanne Liu, the International President of Doctors Without Borders, for a dose of these issues. WATCH FULL INTERVIEW HERE: https://youtu.be/_zyEKRzrO_0 RT LIVE http://rt.com/on-air Subscribe to RT! http://www.youtube.com/subscription_center?add_user=RussiaToday Like us on Facebook http://www.facebook.com/RTnews Follow us on Twitter http://twitter.com/RT_com Follow us on Instagram http://instagram.com/rt Follow us on Google+ http://plus.google.com/+RT Listen to us on Soundcloud: https://soundcloud.com/rttv RT (Russia Today) is a global news network broadcasting from Moscow and Washington studios. RT is the first news channel to break the 1 billion YouTube views benchmark.
Просмотров: 8237 RT
Antidepressant Market in the US 2015 2019
 
00:56
Antidepressant Market in the US 2015 2019 http://www.marketresearchstore.com/report/antidepressant-market-in-the-us-2015-2019-4322 According to the WHO, depression is a common mental disorder which contributes significantly to the global burden of disease. It affects people across communities in the world. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration, as stated by the WHO. Depression can roughly be categorized into six different types. A patient with severe depression can have suicidal thoughts or behaviors. According to a 2012 WHO estimate, approximately 3,000 suicides take place each day, resulting in more than a million deaths per annum. Table of Content 1. Executive Summary 2. List of Abbreviations 3. Scope of the Report 3.1 Market Overview 3.2 Product Offerings 4. Product Profiles 4.1.1 Celexa 4.1.2 Fetzima 4.1.3 Lexapro 4.1.4 Viibryd 4.1.5 Cymbalta 4.1.6 Prozac 4.1.7 Symbyax 4.1.8 Paxil 4.1.9 Wellbutrin 4.1.1 Abilify 4.1.11 Effexor 4.1.12 Pristiq 4.1.13 Zoloft 5. Market Research Methodology 5.1 Market Research Process 5.2 Research Methodology 6. Introduction 7. Disorder Overview 7.1 Depression & its Types 7.1.1 Major Depressive Disorder 7.1.2 Persistent Depressive Disorder 7.1.3 Psychotic Depression 7.1.4 Post-partum Depression 7.1.5 Seasonal Affective Disorder 7.1.6 Bipolar Disorder 7.2 Etiology 7.3 Epidemiology 7.3.1 Bipolar Disorder Among Adults 7.3.2 Dysthymic Disorder Among Adults 7.3.3 Major Depression Among Adults 7.3.4 Major Depression Among Adolescents 7.4 Treatment & Management 7.5 Economic Burden 8. Market Landscape 8.1 Market Overview 8.2 Market Size and Forecast 8.3 Five Forces Analysis 9. Market Segmentation by Mechanism of Action 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 17.1 Competitive Scenario 17.1.1 Key News 17.1.2 Mergers and Acquisitions 17.2 Market Share Analysis 2014 17.2.1 Competitive Assessment of the Top Drugs for Depression 17.2.2 Eli Lilly 17.2.3 Otsuka Pharmaceutical 17.2.4 Pfizer 17.2.5 GlaxoSmithKline 17.2.6 Actavis 17.3 Other Prominent Vendors 18. Key Vendor Analysis 18.1 Actavis 18.1.1 Key Facts 18.1.2 Business Description 18.1.3 Business Segmentation 18.1.4 Business Segmentation by Revenue 2012 and 2013 18.1.5 Sales by Geography 18.1.6 Business Strategy 18.1.7 Key Information 18.1.8 SWOT Analysis 18.2 Eli Lilly 18.2.1 Key Facts 18.2.2 Business Overview 18.2.3 Business Segmentation by Revenue 18.2.4 Sales by Geography 18.2.5 Business Strategy 18.2.6 Key Information 18.2.7 SWOT Analysis 18.3 GlaxoSmithKline 18.3.1 Key Facts 18.3.2 Business Overview 18.3.3 Business Segmentation 18.3.4 Business Segmentation by Revenue 2012 and 2013 18.3.5 Sales by Geography 18.3.6 Pipeline Products 18.3.7 Business Strategy 18.3.8 Key Information 18.3.9 SWOT Analysis 18.4 Otsuka Pharmaceutical 18.4.1 Key Facts 18.4.2 Business Overview 18.4.3 Business Segmentation by Revenue 2014 18.4.4 Business Segmentation by Revenue 2013 and 2014 18.4.5 Geographical Segmentation by Revenue 2014 18.4.6 Business Strategy 18.4.7 Recent Developments 18.4.8 SWOT Analysis 18.5 Pfizer 18.5.1 Key Facts 18.5.2 Business Overview 18.5.3 Business Segmentation by Revenue 2013 18.5.4 Business Segmentation by Revenue 2012 and 2013 18.5.5 Geographical Segmentation by Revenue 18.5.6 Business Strategy 18.5.7 Key Developments 18.5.8 SWOT Analysis
Просмотров: 146 Market Research Store
Free Speech TV | Episode 193 - Saving The American Middle Class - The Ring Of Fire
 
29:00
The Republican Party’s Civil War has hit a new high, or low depending on how you look at it – and we’ll tell you all about it… Democratic Presidential candidates keep talking about the need for a stronger middle class, but we haven’t heard anyone talking about where the middle class actually went. We’ll give you the history tonight… And we’ll give you the details about a whistleblower lawsuit that recently made our roadways a lot safer… Follow more of our stories at http://www.RingofFireRadio.com Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Listen to Ring of Fire on Saturdays from 3pm - 6pm Eastern! Listen live via the Progressive Voices Channel on TuneIn: http://tunein.com/radio/Progressive-Voices-s189055/ Or find a station here: http://www.ringoffireradio.com/station/ Watch Ring of Fire every weekday at 8:30pm EST on Free Speech TV! Support Ring of Fire by subscribing to our YouTube channel: http://www.youtube.com/user/golefttv You can also support us here: http://www.ringoffireradio.com/support/ Your continued support keeps Ring of Fire on the air! Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Support us further by shopping on Amazon via our Amazon-Ring of Fire partnership link. A portion of the sales will come back to Ring of Fire at no extra cost to you. Bookmark and follow the link below and continue shopping as usual! Amazon - Ring of Fire partnership link: http://www.amazon.com/?tag=rinoffir-20
Просмотров: 1251 The Ring of Fire
Apotex International - An Overview
 
06:18
Apotex believes that every man, woman and child is entitled to affordable medical care and freedom from pain and suffering. For close to 40 years, Apotex has met the healthcare challenges of tomorrow and fought hard to build a successful worldwide pharmaceutical company. Through a strategy of vertical integration, Apotex has built an exceptional scientific and manufacturing base that supports a global sales and marketing infrastructure. We have done this on the heels of our continued commitment to excellence. Apotex is focused on meeting the world’s need for the highest quality, affordable medicines. We have built the facilities, the scientific R&D base, and the technology to meet the healthcare needs of the world for today and tomorrow. With an established network of international affiliates and distributors, our medicines are present in more than 115 countries.
Просмотров: 3338 Apotex Inc.
♪♫♪♫ »Study Music - SUPER Memory & Concentration █ Alpha BiNaural Beat - Focus Music
 
01:39:03
Find your study zone with this music to boost your concentration, give you improved focus, better memory. The Alpha BiNaural Beats make it easy to study for tests! Ace your final exams! Download: http://www.healing4happiness.com/downloads/study-music-one-with-alpha-waves-enhanced-learning/ https://geo.itunes.apple.com/us/album/study-music-one-with-alpha-waves-for-super-learning/id1197203106?i=1197203363&mt=1&app=music Study Music One with Alpha Waves for Super Learning With proven results from our solo Alpha BiNaural Beats, I can assure you that with the dedicated study you will get higher grades. Pure alpha binaural beats here: https://www.youtube.com/watch?v=dME_uH9O3HM Best used while studying! As the frequencies alter your concentration while listening. ===► Get Ad-Free Study Music 24/7 + 2 Downloads every Week: https://healing4happiness.com/lp/ftmv1/ ===► Learn How To Have an Exceptional Memory in 30 Days: https://tinyurl.com/H4H-Memory You will need to be wearing headphones or have your speakers at least a meter apart, one facing each ear. Learn how BiNaural Beats work: http://www.healing4happiness.com/binaural-beats/ Check out the research on BiNaural Beats here: http://www.healing4happiness.com/binaural-beats-research-studies/ The frequencies used here are Alpha BiNaural Beats arranged in an 8hz to 12hz sweep. This creates the optimal study aid for super learning, memory retention, and mental alertness. Please Share and Subscribe. Thank You. ©Healing4Happiness 2015 ☯Study Music Study music can help to calm a busy mind which allows for focus on the task at hand. This means you can study without difficulty or distraction. We also include BiNaural Beats in our tracks which gives a huge added bonus to how effective it will be. You memory retention and other cognitive abilities including focus, concentration, attention span etc will be greatly enhanced. Our Alpha BiNaural Beat has been proven to give average higher grades. This is why it will be so helpful when it comes to final exam time! ☯Relaxation With soothing tones and gentle melodies, our music can be the perfect tool to wash away a stressful day. Don't wait until you need a medical (or self medicated) fix to release your anxiety, fear, worry or stress. Frequencies built into this music have been scientifically proven to alter one's state of mind for better well being. ☯Meditation Used for meditation, this music can allow you to find deep stillness inside of yourself. Meditation music can also be used to find higher states of mind, states where a thought comes easily. This is very useful for problem solving, invention or for artists to get into a creative state. Meditation music ranges in pace, quality and composition, so find something that fits with what you are trying to achieve. We have lots of meditation music and music for relaxation on our channel and website. Check it out! ☯Health Spa & Massage You are most welcome to play this music in you Health Spa, Massage or Healing Center. We would appreciate your support if you would like to buy and download from our site. Spa music is very helpful to achieve a pleasant environment for staff and customers and to encourage ultimate relaxation. ☯Healing & Yoga Healing music is a wonderful tool for healing emotional trauma. Many of our tracks will help you search deep inside yourself and make peace with those emotions that need some attention. Music alone can be the catalyst for healing, bringing one into the feeling/emotion that needs a little love to be resolved. This music is perfect to listen to while doing yoga exercises, reiki or any other healing exercises. ☯Sleep Music, Deep Sleep Many of our tracks are examples of sleep music at its best. We also combine the soothing sounds of nature with gentle sleep music, soft voices guiding one into a wonderful dream world and BiNaural Beats. This combination is the key to our successful results. Many listeners and customers find our sleep music and sleep aids to be more effective than pharmaceutical medication or natural medication. If you would like the best night sleep possible, then try one of our sleep tracks in the sleep playlist! ☯BiNaural Beats Healing4Happiness produces BiNaural Beats by themselves and in combination with other audio. All our BiNaural Beats are created to the highest standard using our code for best practice which combines the research of the last 30 years into what you can now hear on our channel. Music thanks to: "Fluidscape" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 http://creativecommons.org/licenses/by/3.0/
Просмотров: 17986031 H4Happiness - Study Music, Relaxing Music
9-1-2015 Brandy Vaughan with Patrick Timpone - Profitable Vaccination with No Liability
 
01:00:12
Source of FULL interview with Patrick Timpone on One Radio Network http://oneradionetwork.com/health/brandy-vaughan-targeted-and-harassed-for-speaking-out-about-forced-vaccination-exposing-what-they-dont-want-the-public-to-know-september-1-2015/ http://www.StopMandatoryVaccination.com MORE: Vaccine Industry's Lies Exposed by an Insider - Brandy Vaughan Interview https://www.youtube.com/watch?v=d6VxikBXcdg The Council for Vaccine Safety is a non-profit organization, founded by a former pharmaceutical representative, aiming to raise awareness of vaccine risks through public education. Let’s face it, we have a broken vaccine system in the US. Toxic vaccines, given in record numbers, are harming our children at epidemic proportions. Yet, as long as vaccines are the only products in the US with complete federal liability protection, there are absolutely no incentives for vaccine makers, aka pharmaceutical companies, to change the way they do things. http://councilforvaccinesafety.org/ -Brandy gives us some background about when she worked at Merck and the scandal and lawsuit about the safety of Vioxx -Vaccine studies are substandard; Brandy tells us why -The ingredients in vaccinations are dangerous; the vaccine makers are not held liable -America gives twice as many vaccines as other developed countries and has a higher infant mortality rate, SIDS rates and chronic health problems among children, like asthma, eczema, allergies, etc. -They’re coming for the adults next; what does this mean? -Why we need to get corporate money out of politics -Outlawing direct to consumer marketing and lobbyists would be a real game changer -Brandy tells us about her non-profit Council for Vaccine Safety: The Council for Vaccine Safety is a non-profit organization, founded by Brandy Vaughan, a former pharmaceutical representative, aiming to raise awareness of vaccine risks through public education. Let’s face it, we have a broken vaccine system in the US. Toxic vaccines, given in record numbers, are harming our children at epidemic proportions. Yet, as long as vaccines are the only products in the US with complete federal liability protection, there are absolutely no incentives for vaccine makers, aka pharmaceutical companies, to change the way they do things. -The intimidation and harassment Brandy has experienced in the past months since she took on SB277 -If you live in CA, you may want to visit www.SB277referendum.com –www.safevax.org is the easy way to get to The Council for Vaccine Safety
Просмотров: 774 Abel Danger
Surprising Blood Test Results (And You're Probably Deficient In It, Too) | VitaLivesFree
 
08:39
You can see the actual numbers here: http://vitalivesfree.com/surprising-blood-test-results/ Hi guys! Last week I was shocked to find out that I was deficient in something that I was sure I was getting plenty of. After researching non-stop, I now know that most of us are at risk and you should all go and have a blood test done, too. This one little sunshine vitamin is responsible for pretty much every single process in the body and anything, from depression to tooth decay to acne, can be caused or exacerbated by it. Please run to your doctor right now and request a blood test or do it privately (it really doesn't cost much). There are also ways you can do it by post. The test you need is called 25-Hydroxyvitamin D (or 25OHD). Don't delay, find out if you need it (I bet you do), and claim your vitality back! Also make sun your best friend. Moderate sun exposure without sunscreen and without burning is the best way to have adequate Vitamin D levels and boost your overall health. I'll be talking much more about Vitamin D in the future and I'll be updating you on my progress (I'll take a follow-up blood test in 3 months), so stay tuned! If you found this video interesting, please share it with your loved ones, so they will also go and get checked out. Have you been diagnosed with Vitamin D deficiency before? How did you raise it up? How are you maintaining it? I'd love to hear from you! Thanks for watching the video! Simply yours, Vita xx SUBSCRIBE for more videos → http://www.youtube.com/user/EcceVita1?sub_confirmation=1 Visit my BLOG → http://vitalivesfree.com WHERE ELSE YOU CAN FIND ME: ------------------------------------------------------ Blog → http://vitalivesfree.com Facebook → http://www.facebook.com/VitaLivesFree Google+ → https://plus.google.com/+Vitalivesfree Twitter → http://www.twitter.com/VitaLivesFree Pinterest → http://www.pinterest.com/VitaLivesFree Instagram → VitaLivesFree Email → vita(at)vitalivesfree.com
Просмотров: 1562 VitaLivesFree
FDA Gives Pfizer Nod for Breast Cancer Drug Two Months Early
 
02:55
Disney, Macy's and Green Mountain Coffee Roasters are in focus in earnings news and Pfizer gets the greenlight from the FDA for a breast cancer drug two months early. Disney posted better than expected earnings and higher revenue in its latest quarter thanks to strong topline numbers from its TV networks and sales of paraphernalia associated with the animated movie Frozen. Macy's is a stock to watch today as it raised its outlook for the year and plans to buy BlueMercury for $210 million in cash. The FDA has granted early approval of Pfizer's drug used to treat advanced stage breast cancer. The approval of Inbrance came two months early. Pfizer needs some big-selling new drugs to boost its earnings, following patent expirations on many of its biggest brands and a relatively thin supply of promising drugs in late-stage trials. Pfizer said the drug is available to order immediately through specialty pharmacies. Keurig Green Mountain Coffee Roasters turns in first quarter earnings results today. KeyBank Capital Markets reiterates its BUY rating on GMCR with a $175 price target. Sales of single K Cups versus sales of brewers are expected to drive numbers. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Просмотров: 158 TheStreet: Investing Strategies
POLICE DEPT. EXPOSE BIG PHARMA SALARIES BUT, WHAT IF IT WAS US?
 
06:51
From an article on Activist Post- fair use: This is great. Great in the sense someone is actually DOING something to combat this constant and ever growing TYRANNY. This police dept. exposed the names, e-mail addresses, and phone numbers of some of America's biggest drug dealers. Great job! I agree absolutely and 100%. So, what's my problem? I thought this goverment was going after whistleblowers? Like Snowden and what's his...err...HER name? I cannot help but, wonder, if WE did this, would we just make the pages of Activist Post or would we be asking Snowden to scoot over?
Просмотров: 16 Medical Menudo420
K Camp - Comfortable
 
03:56
K Camp’s debut album “Only Way Is Up” Available NOW iTunes Deluxe Explicit: http://smarturl.it/KCampOWIUdlxEX Google Play Standard Explicit: http://smarturl.it/KCampOWIUstdEXgp Google Play Standard Clean : http://smarturl.it/KCampOWIUstdEDgp Google Play Explicit Deluxe: http://smarturl.it/KCampOWIUdlxEXgp Google Play Clean Deluxe: http://smarturl.it/KCampOWIUdlxEDgp http://kcamp427.com http://twitter.com/twitter.com/kcamp427 http://facebook.com/kcamp427 http://instagram.com/kcamp427 http://vevo.ly/h1MhCH
Просмотров: 58349611 KCampVEVO
Cyber Hacking in Healthcare & Best Practices for Securing ePHI Webinar | eFax Corporate
 
01:00:44
http://enterprise.efax.com/resources/webinars - This eFax Corporate webinar on "Cyber Hacking in Healthcare & The Best Practices for Securing ePHI in 2015" will reinforce best practice approaches using the widely accepted SANS Security Model. We will discuss a data-centric approach to securing Protected Health Information. Last year alone, over 10 million people in the US were impacted by healthcare industry data breaches. Information housed by covered entities provides fertile ground for hackers because it contains the most valuable information such as names, birthdates – and most importantly – Social Security numbers, which are key pieces of data used by hackers to open new credit lines, create fake medical records, or apply for loans. It’s clear that covered entities are a target of these cyber criminals. Types of breaches and how they occur The stages of a data breach Paradigm shift in data protection Key tips and best practices for securing and transmitting ePHI Contact Us Today to Learn More http://enterprise.efax.com/request-custom-quote Or Call Sales (888) 532-9265
Просмотров: 391 eFax Corporate®
SUPERMODELS SECRETS in a nutshell - Online e commerce beauty store malaysia
 
12:27
Founder of Supermodels Secrets Sdn. Bhd ( http://www.supermodel2u.com ). Online Entrepreneur / Part time Social Media Speaker INSTAGRAM @supermodels_secrets Michelle Chuah founded Supermodels Secrets - a beauty e-tailer in Malaysia since July 2010. With its humble beginnings as a one-man-show blogshop operating from home with only 2 products, she has spearheaded the organic growth of the company to over 600 products and a team of 7 employees with two brick-and-mortar stores over the years primarily via social media marketing and online media. Michelle has been actively involved in social media and digital marketing for more than five years and has a knack for Instagram marketing. She has worked with various companies in the fields of IT, Pharmaceutical sector as well as large commercial companies such as FedEx upon her graduation from the Chartered Institute of Marketing, UK. In year 2008 she left the corporate world due to health reasons - her right eye got blinded from a parasite scar - and got involved in the modelling industry as it was less taxing to her health - her modelling stint soon inspired the birth of Supermodels Secrets offering products for women to look beautiful instantly. Her mission for Supermodels Secrets is to help women look beautiful from head to toe in the shortest time possible in light of today's growing number of busy corporate women. With the volatile online marketing/social media landscape challenging marketeers the world over, Michelle has managed to overcome them with marketing hacks that allows e commerce businesses to flourish in the ever changing marketing environment and can tackle them hands-on, garnering her an invaluable social media marketing experience to grow a successful online business. ◑ My Blog: www.supermodels-secrets.com ◒ My Facebook: http://facebook.com/ilovesupermodel2u ◓ My Instagram: http://instagram.com/supermodels_secrets ◒ My Website: SUPERMODELS SECRETS BEAUTY STORE http://www.supermodelmy.com (Malaysia & Asia online store) http://www.supermodel2u.com (USA, Europe, Australia & other countries)
Просмотров: 1361 Supermodels Secrets
NHALE Inc. (OTC- NHLE) Marijuana Acquisition Company
 
01:09
NHALE Inc (Symbol NHLE) is a U.S. company actively pursuing acquisition opportunities in the rapidly expanding marijuana industry. Nhale acquires companies positioned to make a significant impact within the domestic medical and recreational cannabis market. Nhale provides emerging, proven companies with access to operating talent, tools and leadership to assist in raising their position from start-ups to robust brand leaders.
Просмотров: 502 NHALE Inc